



































Used by Innovation, Partnerships and S&E teams at 15+ of the world's largest pharma companies.
"AcademicLabs maps KOLs, startups and technologies, rank-orders them, and provides the ability to score by criteria of interest. Amazing!"
"By far the best landscaping solution of all we tried."
"Incredible how this broad spectrum of very early to late-stage signals can be analyzed together - grounded in the science - to generate truly insightful landscape reports - and so fast!"



Every CIDP drug, from launched to preclinical, in one picture. 4,264 records across pipeline, trial results, readouts to 2030, developers, IP, experts and funding.

43 companies getting drugs into the brain, scored on nine criteria and ranked into tiers: shuttles, exosomes, nanocarriers, AAV and bypass devices.

63 targets scored on evidence and adoption from 3,070 AI-analysed patents, publications and funded projects. Which are proven, and which are only popular?

Every report reads all the relevant records across researchers, labs, companies, projects, publications, patents, clinical trials and news, and links each figure back to its source.
Four we published recently - entirely free:

4,264 records across all eight types of intelligence, cross-linked down to drug-by-drug trial results. 17 of the 38 readouts due by 2030 land in a single year: 2027.

43 companies getting drugs into the brain, scored on nine criteria: shuttles, exosomes, nanocarriers, AAV and bypass devices. Seven clear the Tier 1 bar.

63 targets scored on evidence and adoption from 3,070 records. Only 14 combine clinical evidence with broad uptake, while MRGPRX2 has 37 patents and just 2 human-evidence records.
All 398 trials with Belgian sites starting in 2026: who runs them, where and on what. Half run only in Belgium, and Brussels, Leuven and Ghent host the most.











Schedule a personalized demo and discover how you can unlock hypertargeted prospecting at scale.